Built to decode the biology of aging.
Founded on the conviction that neurodegeneration is not inevitable, Molsen Therapeutics was built from the ground up to intercept disease at its molecular origins — before irreversible damage takes hold.
We believe neurodegeneration can be intercepted — not just managed.
A platform built for precision, speed, and scale.
Molsen Therapeutics combines optogenetics, medicinal chemistry, and AI-driven computational biology into a single integrated discovery engine. This convergence allows us to map disease-relevant pathways with unprecedented resolution and translate those insights into drug candidates faster than traditional approaches.
Our programs target the earliest molecular events in neurodegeneration — synaptic dysfunction, proteostatic failure, and neuroinflammation — giving patients a chance at intervention before the window closes.
2
Clinical Programs
40+
Scientists
2021
Founded
Company Founded
Molsen Therapeutics launched out of Boston with seed funding and a founding team of neuroscientists and chemists determined to rethink neurodegeneration drug discovery.
First Target Validated
Our integrated platform identified and validated our first novel synaptic target, demonstrating disease-modifying potential in preclinical models of tauopathy.
Series B & IND Filing
Closed an oversubscribed Series B round and filed our first Investigational New Drug application with the FDA for MSX-104 in early-stage Alzheimer’s disease.
Phase 1 Initiated
Dosed the first patient in our Phase 1 clinical trial evaluating MSX-104 safety and pharmacokinetics in healthy volunteers and early AD patients.
Phase 2 Entry & Second Program
Advanced MSX-104 into Phase 2 efficacy studies and brought our second program, MSX-208 for Parkinson’s disease, into IND-enabling studies.
Rooted in Boston's biotech epicenter
Our headquarters in the Cambridge/Boston corridor places us at the heart of the world's densest biotech ecosystem — surrounded by leading academic medical centers, world-class research universities, and a deep network of scientific talent.
This proximity accelerates every dimension of our work: from recruiting exceptional scientists to forging clinical partnerships with the hospitals pioneering neurodegenerative disease research. Boston isn't just where we're located — it's central to how we operate.